Abstract:Abstract Background The gut microbiota plays a central role in host physiology and in several pathological mechanisms in humans. Antibiotics compromise the composition and functions of the gut microbiota inducing long-lasting detrimental effects on the host. Recent studies suggest that the efficacy of different clinical therapies depends on the action of the gut microbiota. Here, we investigated how different antibiotic treatments affect the ability of the gut microbiota to control intestinal inflammation upon fecal microbiota transplantation in an experimental colitis model and in ex vivo experiments with human intestinal biopsies. Results Murine fecal donors were pre-treated with different antibiotics, i.e., vancomycin, streptomycin, and metronidazole before FMT administration to colitic animals. The analysis of the gut microbiome, fecal metabolome, and the immunophenotyping of colonic lamina propria immune cells revealed that antibiotic pre-treatment significantly influences the capability of the microbiota to control intestinal inflammation. Streptomycin and vancomycin-treated microbiota failed to control intestinal inflammation and were characterized by the blooming of pathobionts previously associated with IBD as well as with metabolites related to the presence of oxidative stress and metabolism of simple sugars. On the contrary, the metronidazole-treated microbiota retained its ability to control inflammation co-occurring with the enrichment of Lactobacillus and of innate immune responses involving iNKT cells. Furthermore, ex vivo cultures of human intestinal lamina propria mononuclear cells and iNKT cell clones from IBD patients with vancomycin pre-treated sterile fecal water showed a Th1/Th17 skewing in CD4 + T-cell populations; metronidazole, on the other hand, induced the polarization of iNKT cells toward the production of IL10. Conclusions Diverse antibiotic regimens affect the ability of the gut microbiota to control intestinal inflammation in experimental colitis by altering the microbial community structure and microbiota-derived metabolites.

Microbiota-mediated colonization resistance against intestinal pathogens

The intestinal microbiota: Antibiotics, colonization resistance, and enteric pathogens

Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens

Intestinal Microbiota as a Host Defense Mechanism to Infectious Threats

Diet-Microbe-Host Interactions That Affect Gut Mucosal Integrity and Infection Resistance

Mechanism of the Gut Microbiota Colonization Resistance and Enteric Pathogen Infection

The microbiota: a crucial mediator in gut homeostasis and colonization resistance

Microbial interactions and the homeostasis of the gut microbiome: the role of Bifidobacterium

Control of pathogens and pathobionts by the gut microbiota

Antibiotics promote intestinal growth of carbapenem-resistant Enterobacteriaceae by enriching nutrients and depleting microbial metabolites

Antibiotic Resistance and Microbiota Response

The role of the human gut microbiota in colonization and infection with multidrug-resistant bacteria

An (Anti)-Inflammatory Microbiota: Defining the Role in Inflammatory Bowel Disease?

Immune Responses to Broad-Spectrum Antibiotic Treatment and Fecal Microbiota Transplantation in Mice

Antibiotic-associated dysbiosis affects the ability of the gut microbiota to control intestinal inflammation upon fecal microbiota transplantation in experimental colitis models

Klebsiella Michiganensis Transmission Enhances Resistance to Enterobacteriaceae Gut Invasion by Nutrition Competition

Host-recognition of pathogens and commensals in the mammalian intestine

Gut Microbiota Resilience Mechanisms Against Pathogen Infection and its Role in Inflammatory Bowel Disease

Commensal consortia decolonize Enterobacteriaceae via ecological control

Clostridioides difficile and Gut Microbiota: From Colonization to Infection and Treatment

Colonization resistance: the role of gut microbiota in preventing Salmonella invasion and infection